drugset / Trial / NCT00233532

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

NCT00233532

Phase 4 Completed 2000 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Timeline

Start
2004-03
Primary completion
2005-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject trandolapril Small molecule 4 mg

Indications